theMednetRegister

Dermatology

Hydroxychloroquine   

Questions discussed in this category

How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.
3 Answers available
Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?
1 Answer available
What is your approach to patients with SLE who develop a rash after hydroxychloroquine initiation?
3 Answers available
Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?
Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...
1 Answer available
Do you routinely check G6PD level prior to initiation of hydroxychloroquine?
6 Answers available
How do you manage nausea in the setting of hydroxychloroquine use?
1 Answer available
When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?
2 Answers available
Is there a role for measuring hydroxychloroquine blood levels in clinical practice?
If so, are there specific patient populations for which you would use this metric?
1 Answer available
Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?
1 Answer available
Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?
1 Answer available


Papers discussed in this category

JAMA ophthalmology, 2014-12
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Can J Ophthalmol,
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
J Am Acad Dermatol, 2016 Feb 03
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Int J Clin Pract, 2021 Mar 24
Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
Mod Rheumatol, 2021 Feb 09
QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Heart Rhythm, 2020 Jun 28
Effects of hydroxychloroquine treatment on QT interval.
Arthritis care & research, 2018-03
Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.
J Clin Rheumatol, 2020 Sep 18
Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.
Cureus, 2020 Aug 02
A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.
The Journal of rheumatology, 2015-11
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
Ophthalmology, 2016-06
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Arthritis care & research, 2019-07
Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.
Clin Pharmacol Ther, 2018 Jun
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.
Lupus Sci Med, 2019
Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.
Rev Med Interne, 2016 Oct 13
[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].
Arthritis Rheumatol, 2021 May 02
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Ann Rheum Dis, 2012 Nov 10
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Arthritis Rheum,
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis Rheumatol, 2020 Jan 07
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Support Care Cancer, 2019 Dec 13
Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.
Arthritis Care Res (Hoboken), 2022 Aug 04
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
JAMA dermatology, 2018-10-01
Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
,
Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.
Archives of dermatology, 2002 Sep
Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Clinical rheumatology, 1988 Sep
Treatment of psoriatic arthritis with sulphasalazine: a one year open study.
Journal of the American Academy of Dermatology, 1987 Apr
Gold therapy and its indications in dermatology. A review.
Journal of the American Academy of Dermatology, 2020 May 19
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.
Arthritis & rheumatology (Hoboken, N.J.), 2021 Apr 26
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.

Related Topics in Dermatology

Copyright © 2025 theMednet
All Rights Reserved.